AcrAB多药外排泵与奇异变形杆菌对替加环素（GAR-936）的敏感性降低有关。
AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.
作者信息
Visalli Melissa A, Murphy Ellen, Projan Steven J, Bradford Patricia A
机构信息
Wyeth Research, Pearl River, New York, USA.
出版信息
Antimicrob Agents Chemother. 2003 Feb;47(2):665-9. doi: 10.1128/AAC.47.2.665-669.2003.
Abstract
Tigecycline has good broad-spectrum activity against many gram-positive and gram-negative pathogens with the notable exception of the PROTEEAE: A study was performed to identify the mechanism responsible for the reduced susceptibility to tigecycline in Proteus mirabilis. Two independent transposon insertion mutants of P. mirabilis that had 16-fold-increased susceptibility to tigecycline were mapped to the acrB gene homolog of the Escherichia coli AcrRAB efflux system. Wild-type levels of decreased susceptibility to tigecycline were restored to the insertion mutants by complementation with a clone containing a PCR-derived fragment from the parental wild-type acrRAB efflux gene cluster. The AcrAB transport system appears to be associated with the intrinsic reduced susceptibility to tigecycline in P. mirabilis.
摘要
替加环素对许多革兰氏阳性和革兰氏阴性病原体具有良好的广谱活性，但奇异变形杆菌属是个明显的例外：开展了一项研究以确定奇异变形杆菌对替加环素敏感性降低的机制。两个对替加环素敏感性提高了16倍的奇异变形杆菌独立转座子插入突变体被定位到大肠杆菌AcrRAB外排系统的acrB基因同源物上。通过用包含来自亲本野生型acrRAB外排基因簇的PCR衍生片段的克隆进行互补，使插入突变体恢复到对替加环素敏感性降低的野生型水平。AcrAB转运系统似乎与奇异变形杆菌对替加环素的固有敏感性降低有关。
相似文献
1
AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.
Antimicrob Agents Chemother. 2003 Feb;47(2):665-9. doi: 10.1128/AAC.47.2.665-669.2003.
2
MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli.
J Antimicrob Chemother. 2008 Jan;61(1):46-53. doi: 10.1093/jac/dkm397. Epub 2007 Oct 29.
3
Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2005 Mar;49(3):1017-22. doi: 10.1128/AAC.49.3.1017-1022.2005.
4
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
Antimicrob Agents Chemother. 2009 Feb;53(2):465-75. doi: 10.1128/AAC.00883-08. Epub 2008 Nov 17.
5
RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.
Microb Drug Resist. 2007 Spring;13(1):1-6. doi: 10.1089/mdr.2006.9990.
6
Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).
Antimicrob Agents Chemother. 2004 Jun;48(6):2179-84. doi: 10.1128/AAC.48.6.2179-2184.2004.
7
AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.
Antimicrob Agents Chemother. 2005 Feb;49(2):791-3. doi: 10.1128/AAC.49.2.791-793.2005.
8
Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
J Antimicrob Chemother. 2006 Sep;58(3):673-7. doi: 10.1093/jac/dkl297. Epub 2006 Jul 26.
9
Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae.
PLoS One. 2015 Mar 3;10(3):e0119064. doi: 10.1371/journal.pone.0119064. eCollection 2015.
10
Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli.
J Antimicrob Chemother. 2003 Mar;51(3):545-56. doi: 10.1093/jac/dkg126.
引用本文的文献
1
RND/HAE-1 members in the Pseudomonadota phylum: exploring multidrug resistance.
Biophys Rev. 2025 Mar 7;17(2):687-699. doi: 10.1007/s12551-025-01297-8. eCollection 2025 Apr.
2
Mechanisms of tigecycline resistance in Gram-negative bacteria: A narrative review.
Eng Microbiol. 2024 Aug 17;4(3):100165. doi: 10.1016/j.engmic.2024.100165. eCollection 2024 Sep.
3
Genomic profiling of pan-drug resistant proteus mirabilis Isolates reveals antimicrobial resistance and virulence gene landscape.
Funct Integr Genomics. 2024 Sep 3;24(5):154. doi: 10.1007/s10142-024-01419-7.
4
Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps.
ACS Infect Dis. 2024 May 10;10(5):1458-1482. doi: 10.1021/acsinfecdis.4c00091. Epub 2024 Apr 25.
5
Case report: A successfully treated case of community-acquired urinary tract infection due to in Bangladesh.
Front Med (Lausanne). 2023 Jun 26;10:1206756. doi: 10.3389/fmed.2023.1206756. eCollection 2023.
6
Tripartite efflux pumps of the RND superfamily: what did we learn from computational studies?
Microbiology (Reading). 2023 Mar;169(3). doi: 10.1099/mic.0.001307.
7
Isolation and Characterization of Lytic Virus 309.
Viruses. 2022 Jun 15;14(6):1309. doi: 10.3390/v14061309.
8
Intrinsic resistance: A non-negligible bacterial trait.
Ann Med Surg (Lond). 2022 Jun 3;78:103949. doi: 10.1016/j.amsu.2022.103949. eCollection 2022 Jun.
9
The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.
Pharmaceutics. 2021 Dec 5;13(12):2085. doi: 10.3390/pharmaceutics13122085.
10
Efficacy of Tigecycline and Linezolid Against Pan-Drug-Resistant Bacteria Isolated From Companion Dogs in South Korea.
Front Vet Sci. 2021 Aug 6;8:693506. doi: 10.3389/fvets.2021.693506. eCollection 2021.
本文引用的文献
1
Replica plating and indirect selection of bacterial mutants.
J Bacteriol. 1952 Mar;63(3):399-406. doi: 10.1128/jb.63.3.399-406.1952.
2
Gene expression response to misfolded protein as a screen for soluble recombinant protein.
Protein Eng. 2002 Feb;15(2):153-60. doi: 10.1093/protein/15.2.153.
3
Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae.
J Antimicrob Chemother. 2002 Apr;49(4):625-30. doi: 10.1093/jac/49.4.625.
4
High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.
Antimicrob Agents Chemother. 2000 Dec;44(12):3441-3. doi: 10.1128/AAC.44.12.3441-3443.2000.
5
Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli.
Antimicrob Agents Chemother. 2000 Nov;44(11):3210-2. doi: 10.1128/AAC.44.11.3210-3212.2000.
6
Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium.
Antimicrob Agents Chemother. 2000 Nov;44(11):3118-21. doi: 10.1128/AAC.44.11.3118-3121.2000.
7
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9. doi: 10.1128/AAC.44.8.2225-2229.2000.
8
Antibiotic efflux pumps.
Biochem Pharmacol. 2000 Aug 15;60(4):457-70. doi: 10.1016/s0006-2952(00)00291-4.
9
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
10
Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
Antimicrob Agents Chemother. 2000 Apr;44(4):1085-8. doi: 10.1128/AAC.44.4.1085-1088.2000.
Zotero 插件